Bosnia and Herzegovina vs Singapore: Treatment success rate for patients treated for MDR-TB
Bosnia and Herzegovina
33.0%
in 2022
Singapore
39.0%
in 2022
Bosnia and Herzegovina rank
151st
Singapore rank
150th
Treatment success rate for patients treated for MDR-TB over time
- Bosnia and Herzegovina
- Singapore
How they compare
Singapore currently reports 39.0% against 33.0% in Bosnia and Herzegovina, a difference of 6.0%.
That makes Singapore's figure about 1.2 times Bosnia and Herzegovina's.
The two have swapped places 2 times across 8 shared years of data; in 2009 it was Singapore ahead.
Bosnia and Herzegovina ranks 151st and Singapore ranks 150th of 163 countries.
Across the 3 decades both report, Bosnia and Herzegovina averaged higher in 1 and Singapore in 1.
Head to head by decade
| Decade | Bosnia and Herzegovina | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 100.0% | 0.0% | — |
| 2010s | 64.5% | 58.8% | 5.7% | Bosnia and Herzegovina |
| 2020s | 33.0% | 39.0% | 6.0% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Bosnia and Herzegovina or Singapore?
- Singapore, at 39.0% against 33.0% in Bosnia and Herzegovina as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Bosnia and Herzegovina and Singapore?
- 6.0%, with Singapore ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Singapore?
- 8 years are reported by both, from 2009 to 2022.
- How do Bosnia and Herzegovina and Singapore rank globally for treatment success rate for patients treated for mdr-tb?
- Bosnia and Herzegovina ranks 151st and Singapore ranks 150th of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.